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Abstract
Multiple myeloma (MM) remains an incurable disease despite improvements to available treatments and efforts to identify
new drug targets. Consequently new approaches are urgently required. We have investigated the potential of native
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), in combination with doxorubicin, to induce apoptotic cell
death in phenotypically distinct populations of myeloma cells in vitro and in vivo. The cytotoxic potential of TRAIL alone, and
in combination with DOX, was assessed in vitro in purified CD138+ and CD1382 cells from the MM cell lines and samples
from patients with MM. Mouse xenografts obtained by implanting CD1382 MM cells were used to assess the efficacy of
TRAIL, alone and in combination with DOX, in vivo. CD1382 cells were shown to be more resistant to the cytotoxic activity of
TRAIL than CD138+ cells and have reduced expression of TRAIL death receptors. This resistance results in preferential killing
of CD 138+ cells during exposure of MM culture to TRAIL. Furthermore, prolonged exposure results in the appearance of
TRAIL-resistant CD1382 cells. However, when TRAIL is combined with doxorubicin, this results in complete eradication of
MM cells in vivo. Most importantly, this treatment successfully eliminates CD1382 cells implicated in tumour initiation and
growth maintenance. These findings may explain the failure of current therapies and offer a promising new approach in the
quest to cure MM and disseminated cancers.
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Introduction
Multiple myeloma (MM) is a clonal B cell malignancy
characterised by the accumulation of plasma cells in the bone. It
is the second most prevalent blood cancer and accounts for
approximately 10% of all haematological cancers [1]. MM is
characterised by the development of osteolytic lesions, anaemia
and immunosuppression.
MM cells are typically found in multiple bone marrow sites.
Thus, only systemic treatments, such as chemotherapy or
irradiation are likely to result in substantial tumour reduction
and remission. However, despite developments in treatment,
current strategies have not been successful in the complete
eradication of malignant plasma cells, and MM remains an
incurable disease. Median survival with conventional chemother-
apy (malphalan+prednisone) regimens is approximately 3 years [2]
and more aggressive chemotherapy is associated with only
a modest improvement [3,4]. High-dose therapy with stem cell
transplantation improves response and long-term remission in
younger patients, but results in only a modest survival advantage
compared to conventional therapy [5]. More recently, the
introduction of new, targeted, therapies such as lenalidomide
and bortezomib, has resulted in increased survival, however, even
with these new agents patients ultimately relapse [6,7]. In addition,
treatment with some chemotherapeutic drugs is associated with
the appearance of secondary malignancies [8–10] suggesting that
new approaches are urgently required.
Recent advances in our understanding of the origin and
development of malignant transformation has highlighted the
importance of tumour-initiating cancer ‘‘stem’’ cells. These cells
may explain the failure of current approaches to cancer treatment
[11,12]. An important feature of these cells is their relative
quiescence. Conventional chemotherapeutic agents often target
rapidly dividing cancer cells and leave normal cells unharmed. It
follows that the differentiated, rapidly dividing cancer cells, which
represent the majority of cells within the tumour, are compara-
tively easy to treat when compared to the slow dividing tumour-
initiating cells. Furthermore, survival and development of drug
resistance in this population could further limit future therapeutic
options. The existence of these cells has been reported in a variety
of cancers, including acute myeloid leukaemia, breast, prostate
and myeloma [13–16].
Early work in MM has demonstrated that only a small
proportion of cells are capable of clonogenic colony-forming
growth [17]. The hypo-proliferative nature of myeloma has led to
the hypothesis that the bulk of the tumour results from
a transformed B cell with the capacity for both self-renewal and
production of terminally differentiated progeny [18]. Recently, it
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has been shown that clonogenic progenitor cells can be successfully
isolated from established MM cell lines as well as from patient
bone marrow samples [16]. Furthermore, it has been reported that
syndecan 1 negative cells (CD1382), which represent only a minor
fraction of MM cells, possess the capacity for unlimited self-
renewal in vitro and the capacity to induce tumour growth in vivo
[16].
There is increasing evidence to indicate that the process of
apoptosis plays a central role in tumour establishment and
resistance to chemotherapy [19–23]. It has been suggested that
anticancer drugs that induce apoptosis in tumour cells by
activation of the death receptor pathway may offer an improved
treatment for patients with MM [24–26]. Tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL/Apo2L) belongs to the
tumour-necrosis factor (TNF) super-family of related proteins [27].
TRAIL functions as a homotrimer and mediates its biological
activity through four TRAIL receptors [28]. Two of these
receptors, TRAIL R1 and TRAIL R2, contain death domain
motifs and promote apoptosis. TRAIL binding to R1 or R2 results
in signalling through the death-inducing signalling complex and
induces apoptosis in tumour cells but not normal cells [29–30],
suggesting that one of the normal physiological roles of TRAIL is
in immune surveillance [31–33]. Importantly, it has been shown
that myeloma cells can develop resistance to TRAIL [34–35];
however, conventional chemotherapeutic drugs can sensitise these
resistant cells to TRAIL through up-regulation and activation of
death receptors R1 and R2 [35–36]. Indeed, the anthracycline
antibiotic, doxorubicin (DOX) has been shown to have the
greatest potential for sensitisation of tumour cells to TRAIL [37–
38]. Whether all cells develop resistance to TRAIL or whether this
is limited to those with tumour-initiating potential is unclear.
We have previously reported the expression and purification of
native human TRAIL in E. coli [39]. Furthermore, we, and others,
have shown that TRAIL induces apoptosis in human multiple
myeloma cells [34–36,40,41]. However, it is unclear whether
TRAIL has similar effects in both CD138+ and CD1382
populations and whether combination with chemotherapeutic
agents increases the sensitivity of myeloma cells to TRAIL.
Therefore, the aim of the present study was to determine whether
recombinant human TRAIL could induce apoptosis in CD138+
and CD1382 cells and whether TRAIL in combination with
DOX could cause sustained eradication of human MM cells in vitro
and in vivo.
Materials and Methods
Ethics statement
Bone marrow samples were obtained from patients with
multiple myeloma after obtaining informed written consent (South
Sheffield Research Ethics Committee (SSREC) reference 05/
Q2305/96). All treatment protocols involving animals were
approved by the UK Home Office (project licence PPL 40/2901).
Reagents
TRAIL was expressed and purified as we previously described
[39]. Doxorubicin and dexamethasone were purchased from
Sigma (Poole, UK). Reagents were dissolved in culture media such
that identical volumes were used within experiments.
Cell culture
The human MM cell lines, RPMI8226 and NCI H929 were
obtained from the American Type Culture Collection (Rockville
MD, USA) and the OPM-2 line from the German Collection of
Microorganisms and Cell Cultures (Braunschweig, Germany).
Cells were maintained in RPMI 1640 medium (Life Technologies)
supplemented with 10% foetal bovine serum, 1% penicillin/
streptomycin, 1% sodium pyruvate, and 1% nonessential amino
acids. Cells were incubated at 37uC, with saturated humidity and
an atmosphere of 5% CO2.
Patient samples
Bone marrow samples were obtained from patients (3 male, 2
female, mean age 70.2 years), with newly diagnosed multiple
myeloma, after obtaining informed written consent (SSREC
reference: 05/Q2305/96). These patients had not previously
undergone treatment. The mononuclear cell fraction was isolated
by density gradient centrifugation over Lymphoprep according to
manufacturer instructions (Nycomed Pharma, Oslo, Norway).
Separation of CD138+ and CD1382 cells
Purification was performed as described previously [16]. Briefly,
CD138+ cells were obtained from cultures of RPMI8226, NCI
H929 or OPM2 cells, or patient mononuclear cell samples, by
immunomagnetic separation. Cells were incubated with microbe-
ads conjugated with anti-human CD138 antibodies and separated
using a magnetic column (Miltenyi Biotec, Bisley, UK). CD1382
cells were obtained after depletion of CD138+ cells from the
culture. CD1382 cells isolated from patient bone marrow samples
were defined as cells within the fraction that were CD1382 and
CD342. CD1382CD342 cells were obtained after immunomag-
netic depletion of the CD1382 mononuclear fraction of normal
haematopoietic cells using mouse anti-human CD34 antibodies
coupled to microbeads (Miltenyi Biotec).
Determining the cytotoxic effects of TRAIL, doxorubicin
(DOX) and dexamethasone (DEX) on CD138+ and
CD1382 myeloma cells
The ability of TRAIL, DOX, DEX or TRAIL in combination
with DOX to reduce cell viability was determined using
a colorimetric assay as reported previously [39]. Briefly, each
compound was diluted in 50 ml of RPMI1640 culture media and
added to the wells of a 96-well tissue culture plate containing
CD138+ or CD1382 cells (26105 per 50 ml) and incubated for
48 h at 37uC. Twenty microlitres of CellTiter96R Aqueous One
Solution Reagent containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and
phenazine ethosulfate (PES) (Promega, Madison, WI) were added
to each well. Absorbance at 490 nm was measured after 2 or 4 h.
Wells containing cells only and wells containing medium only were
used as controls.
Cell preparation and staining for microscopic
examination
RPMI 8226 cells were washed in PBS and 0.16105 cells re-
suspended in 0.2 ml of PBS and cytospun onto glass slides. Cells
were fixed in 0.2 ml of 4% paraformaldehyde for 10 minutes at
room temperature and washed again in PBS (62). Cells were
stained with haematoxylin and eosin, dehydrated through ethanol
and xylene, mounted with DPX (Fisher Scientific, UK) and
examined under light microscopy using640 objective.
Assessment of apoptosis by annexin V labelling and flow
cytometric analysis
The ability of TRAIL to induce apoptosis of myeloma cells was
assessed by flow cytometric analysis of APC-conjugated annexin V
and 7-aminoactinomycin D (annexin V-APC/7 AAD) stained
cells. Cells (16105/ml) were grown for 18 hours and then left
Eradication of MM Cells
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e35830
untreated or treated with TRAIL (100 ng/ml) for 6 hours. Cells
were washed twice in PBS and labelled with annexin V-APC/7
AAD for 15 minutes and immediately analysed by flow cytometry.
Cells negative for both 7AAD and annexin V-APC staining are
live cells, 7AAD negative, annexin V-APC positive cells are early
apoptotic cells, whereas, 7AAD-positive, annexin V-APC-positive
stained cells are cells in the late stages of apoptosis or dead.
The effect of DOX (500 ng/ml) on apoptosis of myeloma cells
treated cells was assessed by fluorescein isothiocyanate-conjugated
annexin V and TO-PRO-3 iodide (annexin V-FITC/TOPRO 3)
labelling to avoid a DOX interference with the detection of
annexin V-APC/7 AAD labelling.
Measurement of caspase activity
Caspase 3+Caspase 7 activity was determined using the
Caspase-GloH 3/7 Assay (Promega, Madison, WI) according to
manufacturer’s instructions. The assay provides a luminogenic
caspase 3/7 substrate, which contains the caspase recognisable
tetrapeptide sequence DEVD. Addition of Caspase-GloH 3/7
reagent results in cell lysis, followed by caspase cleavage of the
substrate and release of aminoluciferin, a substrate for luciferase.
The luminescence produced is proportional to the amount of
caspase activity present. For each assay sample 16105 cells per
millilitres were aliquoted into a single well of a 24-well plate and
maintained for 18 hours. RPMI8226, NCI H929 and OPM2 cells
were treated with DOX (50 and 500 ng/ml for 6 hours), TRAIL
(100 ng/ml for six hours) or with DOX (50 ng/ml) for 12 hours
followed by TRAIL treatment (10 ng/ml for 6 hours). Twenty-five
microlitres of each samples was transferred into a single well of
a 96-well plate and 25 microlitres of Caspase-GloH 3/7 Assay
mixture added. After incubation for 30 minutes at 22uC lumines-
cence was measured using a SpectraMax 5 luminometer/plate
reader. All treatments were performed in triplicate and the
measured luminescence signal (in luminescence relative units or
LRU) was used as a direct measurement of caspase activity.
Background readings were determined from wells containing
culture medium alone and subtracted from each sample reading.
Caspase 8 and caspase 9 activity was determined using the
Caspase-GloH 8 and the Caspase-GloH 9 Assays, respectively,
(Promega, Madison, WI) according to manufacturer’s instructions
and the above protocol.
Measurement of the effect of TRAIL on the relative ratio
of CD138+ and CD1382 cell populations in culture
Exponential cultures of RPMI8226 cells were divided into two
aliquots. In one aliquot CD138+ and CD1382 cells populations
were separated as described above and cell number determined.
The second aliquot was treated with TRAIL (25 ng/ml) and
incubated for a further 48 h. CD138+ and CD1382 cells were
then isolated using immunomagnetic separation and cell numbers
determined. Data are expressed relative to the untreated samples.
Generation of TRAIL-resistant CD138+ and CD1382 cells
in vitro
RPMI8226 cells were grown in the presence of TRAIL (25 ng/
ml). Surviving cells were transferred to a fresh medium containing
TRAIL every 5 days. After 10 cycles of treatment the CD138+ and
CD1382 cells were isolated by immunomagnetic separation. The
cytotoxic activity of TRAIL was determined on CD138+ and
CD1382 cells isolated from TRAIL-resistant culture and com-
pared to CD138+ and CD1382 cells isolated from parental
TRAIL-sensitive RPMI8226 culture.
Measurement of TRAIL receptor expression
Separated CD138+ and CD1382 RPMI8226, NCI H929 and
OPM2 cells were incubated with mouse anti-human TRAIL
receptor R1 and R2 phycoerythrin (PE)-conjugated monoclonal
antibody. Flow cytometric analysis was performed on a FACSCa-
libur (BD Biosciences, Oxford, UK) using the Cellquest (acquisi-
tion) and the Flowjo (data analysis) software packages.
Determining the effect of TRAIL, DOX and TRAIL in
combination with DOX on myeloma cell growth in vivo
All studies were performed using a non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mouse xenograft
model. Female mice (8–10 weeks of age) were first irradiated with
300 Rad using a 137Cs irradiator. Separated CD1382 RPMI8226-
GFP cells (16106 in 0.1 ml PBS) were prepared as described
above and were injected subcutaneously into the right flank of
NOD/SCID mice 24 h post irradiation. After formation of
palpable tumours mice were randomised into four groups and
treated each day for five consecutive days by subcutaneous
injection with one of four treatments. The first group (control,
n = 5) received 100 m PBS only, the second (DOX, n= 5) received
DOX (1 mg/kg) and the third (TRAIL, n= 5) TRAIL (10 mg/kg).
The fourth group (DOX+TRAIL, n = 10) received DOX on the
first and third day only (1 mg/ml) and TRAIL (10 mg/kg) on each
day.
Body weight was monitored continuously and used as an
indicator of systemic toxicity and general health status. Tumour
growth was assessed by measuring tumour size on digitalised
images of tumours taken by LIGHTool imaging system (Lightools
Research, CA, USA) at regular intervals. Each picture of tumour
was first magnified to facilitate subsequent manipulations. The
IMAGEJ software (http://rsb.info.nih.gov/ij/) was used to
calculate size and average brightness of the tumour area. The
product (area size multiplied by average area brightness) was used
as a measure of the tumour size of the particular tumour at the
specific time point. The mean value for tumour size for each
experimental group at a given time point was calculated. Tumour
growth was monitored on each day during the treatment week and
then every second day for the following three weeks. Mice in the
PBS, DOX and TRAIL group were sacrificed at day 55 after
tumour cell inoculation. At sacrifice, tumour burden was
measured by the LIGHTools imaging system and individual
organs examined for evidence of tumour growth. Mice in group
four (TRAIL plus DOX combination) were monitored for at least
90 days from the start of the treatment.
Statistical analysis
Comparisons between groups were determined by Student’s t-
test or analysis of variance as appropriate (GraphPad Prism
software). All data represent the mean 6 standard deviation.
Results
CD138+ RPMI8226 cells are more sensitive to TRAIL than
to DOX and DEX
To determine the activity of our native TRAIL preparation we
compared the sensitivity of CD138+ RPMI8226 cells, isolated
from the parent population, to increasing concentrations of
TRAIL and compared it to that of DOX or DEX using an
MTS cytotoxicity assay (Fig. 1). CD138+ RPMI8226 cells
represent 97–99% of the unselected population and have similar
characteristics to the unselected population, i.e. treatment with
TRAIL or DOX results in similar levels of cytotoxicity. DEX was
Eradication of MM Cells
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included as a positive control as this compound is used in clinical
practice to treat MM. Treatment of CD138+ cells with TRAIL,
DOX or DEX was associated with a dose-dependent increase in
cytotoxicity (p,0.0001 for TRAIL and DOX and p,0.0129 for
DEX) (Fig. 1). The cytotoxic effect of TRAIL was more
pronounced, causing a 50% reduction in cell viability at
a concentration of 5 ng/ml. In contrast, doses of 500 ng/ml of
DOX were required to induce 50% cytotoxicity of CD138+ cells.
DEX had only a modest ability to reduce viability of CD138+ cells
as concentrations as high as 500 ng/ml were only able to induce
20% cytotoxicity.
Sensitivity of CD138+ RPMI8226 cells to TRAIL is
increased by pre-incubation with doxorubicin
Since both TRAIL and DOX were shown to dose-dependently
increase cytotoxicity of CD138+ cells we chose to establish whether
DOX could increase their sensitivity to TRAIL. Purified CD138+
RPMI8226 cells were incubated with increasing concentrations of
TRAIL alone (5, 10 and 25 ng/ml) after pre-incubation with
DOX (500 ng/ml) for varying times (Fig. 2). This pre-incubation
regime was chosen as this approach has been shown to have
a higher potential to sensitise cells to TRAIL than when both
agents are being given simultaneously [38]. Pre-incubation was
performed for 6, 12, or 24 h and incubation with TRAIL
continued for an additional 24 h. (Fig. 2). DOX significantly
augmented TRAIL cytotoxicity at all TRAIL concentrations used
when compared to TRAIL alone. The magnitude of augmentation
increased with duration of the pre-incubation period. The highest
relative increase in cytotoxicity was detected at the lowest
concentration of TRAIL (5 ng/ml).
Apoptotic cell death is the mechanism of TRAIL-induced
cytotoxicity
Assessment of apoptosis in RPMI8226, NCI H929 and OPM2
cells was determined by annexin V labelling and flow cytometric
analysis. Apoptosis of TRAIL treated myeloma cells was assessed
by flow cytometric analysis of APC-conjugated annexin V and 7-
aminoactinomycin D (annexin V-APC/7 AAD) staining (Fig. 3A).
The cells (16105/ml) were grown for 18 hours and then left
untreated or treated with TRAIL (100 ng/ml) for 6 hours. Cells
negative for both 7AAD and annexin V-APC staining are live cells
(the number in the bottom left quadrant indicate the percentage),
7AAD negative, annexin V-APC positive staining cells are early
apoptotic cells (bottom right quadrant), 7AAD-positive, annexin
V-APC-positive staining cells are cells in the late stages of
apoptosis or dead (top right quadrant). TRAIL-induced apoptosis
in all three cell lines (Fig. 3).
DOX treated (500 ng/ml) cells were assessed by fluorescein
isothiocyanate-conjugated annexin V and TO-PRO-3 iodide
(annexin V-FITC/TOPRO 3) labelling to avoid a strong DOX
interference detected with the annexin V-APC/7 AAD labelling
(Fig. 3B). DOX induced apoptosis in all three cell lines, however
the level of induction was lower compared to TRAIL-induced
apoptosis.
Microscopic examination of haematoxylin and eosin stained
cells revealed the morphological differences between untreated
and TRAIL-treated RPMI8226 cells. Untreated cells had defined
rounded nuclei and uniformly stained cytoplasm (Fig. 4A). In
contrast, TRAIL-treated cells showed typical signs of apoptosis
with condensed and fragmented nuclei and blebbing or detaching
of cytoplasm (Fig. 4B).
To confirm exposure to TRAIL results in apoptosis we
measured the activity of caspase 3 and caspase 7, enzymes
involved in apoptotic signal transduction. TRAIL treatment
resulted in an induction of caspase activity when compared to
untreated control cells in each line (p,0.001) (Fig. 4C). In
contrast, DOX treatment had no effect on caspase activity in NCI-
H929 and OPM2 cells and only a modest effect in RPMI8226
(p,0.05).
Figure 1. In vitro sensitivity of the purified CD138+ RPMI8226
cells to DOX, TRAIL and DEX. After immunomagnetic separation of
CD138+ RPMI8226 cells from the parent population, cells (16105 /ml)
were incubated with increasing concentrations of TRAIL (1–100 ng/ml),
Doxorubicin (DOX, 10–1000 ng/ml), or Dexamethasone (DEX, 10–
500 ng/ml) for 48 h. DEX was included as a positive control.
Cytotoxicity was measured by MTS assay and expressed as a percentage
of the untreated control sample. For details see Materials and Methods.
Data represent the mean 61SD of the three independent experiments.
doi:10.1371/journal.pone.0035830.g001
Figure 2. In vitro sensitivity of CD138+ RPMI8226 cells to TRAIL
alone, or TRAIL after pre-incubation with DOX. Following
immunomagnetic separation, CD138+ cells (16105 /ml) were incubated
with increasing concentrations of TRAIL alone (5, 10 and 25 ng/ml) for
24 h (black bars), or TRAIL for 24 h after initial pre-incubation with DOX
(500 ng/ml) for 6, 12 or 24 h (white bars). Cytotoxicity was measured by
MTS assay and expressed as a percentage of the untreated control
sample. For details see Materials and Methods. Data represent the mean
61SD of the three independent experiments.
doi:10.1371/journal.pone.0035830.g002
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TRAIL induces myeloma cell death by activating both
extrinsic and intrinsic pathways of apoptosis
To determine the molecular mechanism of TRAIL and DOX
induced apoptosis the activity of caspase 8 (early initiator caspase
of the extrinsic or death receptor mediated pathway), caspase 9
(early initiator caspase of the intrinsic pathway involving
mitochondria) and combined activity of caspase 3 and caspase 7
(effector caspases activated by both pathways) was measured after
exposure of RPMI8226 cells to TRAIL and compared with
untreated cells. TRAIL was shown to be a potent activator of both
extrinsic and intrinsic pathways (Fig. 5). In contrast, DOX
activates only the intrinsic pathway and the level of activation is
lower than the TRAIL-mediated activation of the same pathway.
CD1382 cells are less sensitive to the cytotoxic activity of
TRAIL, either alone or in combination with doxorubicin,
when compared to CD138+ cells
To determine whether the same sensitivity to TRAIL is present
in the minor fraction of MM cells (2–3% of the total), we next
compared the relative sensitivity of CD1382 and CD138+ cells.
Cytotoxicity was measured after exposure of CD1382 and
CD138+ RPMI8226, NCI H929 and OPM2 cells to TRAIL
and DOX alone or after pre-incubation with DOX followed by
TRAIL treatment (Fig. 6A, 6B and 6C). CD1382 cells were more
resistant to the actions of TRAIL than CD138+ cells in each of the
cell lines (p,0.01). TRAIL remained a potent inducer of
cytotoxicity and this activity was further enhanced by pre-
incubation of cells with DOX.
Exposure of myeloma cells to TRAIL results in preferential
killing of CD138+ compared to CD1382 cells
To determine whether reduced sensitivity of CD1382 cells to
TRAIL has any relative survival advantage over CD138+cells, we
investigated the relative level of reduction of CD138+ and
CD1382 cell fractions in growing cultures of un-separated cells
after exposure to TRAIL. Unsorted RPMI8226 culture was used
in this experiment and treated with TRAIL (25 ng/ml) for
48 hours. One half of the culture prior to TRAIL exposure as well
as the remaining TRAIL-treated half was used for immunomag-
netic cell separation. After separation, the total numbers of
CD138+ and CD1382 cells were determined before and after
exposure of cultures to TRAIL. When exposed to TRAIL, the
total number of cells (CD138++CD1382) was reduced from 100%
to 960.7% (91% reduction) (Fig. 7A). However, the number of
CD1382 cells was reduced proportionally less than CD138+ cells:
to 8662.2% for CD1382 and to 7610.4% for CD138+ (14% and
Figure 3. Flow cytometric analysis of Annexin V labelled myeloma cells after treatment with TRAIL or DOX. The RPMI8226, NCI H929
and OPM2 cells (16105/ml) were grown for 18 hours and then left untreated or treated with TRAIL (100 ng/ml) (3A) or DOX (500 ng/ml) (3B) for
6 hours. Cell death was assessed by annexin V staining and cellular uptake of either 7AAD for TRAIL treatment (Fig. 3A) or TOPRO3 for DOX treatment
(Fig. 3B). In vitro apoptosis of myeloma cells was assessed by flow cytometric analysis of annexin V-APC/7 AAD stained cells (TRAIL treated) or annexin
V-FITC/TOPRO3 stained cells (DOX treated).
doi:10.1371/journal.pone.0035830.g003
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93% reduction respectively, p,0.0001) (Fig. 7B). This dispropor-
tional reduction in the number of CD1382 cells resulted in their
relative increase from 3% to 45% of the total number of cells in
the culture (initial ratio 1:33 reduced to 1:1.2).
Prolonged incubation of MM cells with TRAIL results in
the appearance of TRAIL-resistant CD1382 cells
The appearance of TRAIL-resistant cells has been reported
previously, however the nature of this resistance, from the point of
the existence of two distinct cell populations has not been
investigated. We wanted to determine whether this resistance also
appears in the CD1382 population. Therefore to facilitate the
development of TRAIL-resistant culture we deliberately chose
growth conditions, which favour the appearance of resistant cells
(low concentration of TRAIL and prolonged exposure). Resistant
RPMI8226 cells were obtained after continuous exposure of
parental TRAIL-sensitive RPMI8226 culture to TRAIL (25 ng/
ml, for 10 cycles of 5 days culture). Measurement of cell number
and construction of growth curves showed that there was no
significant difference between parental cells and TRAIL resistant
cells (data not shown). Of these cells 96.25% were CD138+ and
3.75% CD1382. CD138+ and CD1382 cells from TRAIL-
resistant culture were isolated using immunomagnetic separation
and their susceptibility to TRAIL (25 ng/ml) compared to the
parental, TRAIL-sensitive culture. CD138+ and CD1382 cells
isolated from TRAIL-resistant culture were shown to be resistant
to TRAIL (Fig. 7D).
Figure 4. Morphological changes and caspase activity in RPMI8226 cells undergoing apoptotic cell death after exposure to TRAIL.
Cells (16105/ml) were grown for 18 hours and then left untreated or treated with TRAIL (100 ng/ml) for 6 hours. Untreated (A) and TRAIL-treated cells
(B) were cytospun onto microscopic slides, stained with haematoxylin (nuclei) and eosin (cytoplasm) and examined under light microscopy using640
objective. Apoptotic cells are indicated by an arrow. (C) Induction of effector caspase3+effector caspase 7 activities in RPMI8226 myeloma cells after
treatment with TRAIL or DOX. The cells (16105/ml) were grown for 18 hours and then left untreated or treated with TRAIL (100 ng/ml) or DOX
(500 ng/ml) for 6 hours. Data represent the mean 61SD of the three independent experiments.
doi:10.1371/journal.pone.0035830.g004
Figure 5. Initiator Caspase 8 and initiator caspase 9 activity in
RPMI 8226, NCI H929 and OPM2 cells after TRAIL or DOX
treatment. Cells were grown for 18 hours and treated with DOX
(500 ng/ml) or TRAIL (100 ng/ml) for 6 hours or left untreated as
control samples. The caspase-GloH 3/7, caspase-GloH 8 or caspase-GloH
9 Reagent (50 ml) was added directly to each well of 96-well plate
containing 50 ml of cells. The plate was incubated at 22uC and
luminescence was recorded after 30 minutes. Caspase activities were
expressed in relative luminescence units (RLU) as direct readings from
the luminometer. Data represent the mean 61SD of the three
independent experiments. * = p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0035830.g005
Eradication of MM Cells
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CD1382 cells have lower levels of expression of TRAIL
receptor R1 and R2 than CD138+ cells
To determine whether the differences in sensitivity to TRAIL
were a reflection of differences in expression of TRAIL receptors,
both CD138+ and CD1382 RPMI8226, NCI H929 and OPM2
cell populations were labelled with anti-TRAIL R1 and R2 PE-
conjugated antibodies and analysed by a flow cytometry. FACS
Figure 6. In vitro sensitivity of purified CD138+ and CD1382
myeloma cells to DOX and TRAIL alone, or TRAIL after pre-
incubation with DOX. After immunomagnetic separation, CD138+
and CD1382 RPMI8226 (A), NCI H929 (B) and OPM2 (C) cells (16105 /ml)
were incubated with DOX (500 ng/ml) and TRAIL (25 ng/ml) alone for
24 h, or TRAIL for 24 h after initial pre-incubation with DOX (500 ng/ml)
for 24 h. Cytotoxicity was measured by MTS assay and expressed as
a percentage of the untreated control sample. For details see Materials
and Methods. Data represent the mean61SD of the three independent
experiments.* = p,0.05
doi:10.1371/journal.pone.0035830.g006
Figure 7. Relative difference in number of CD138+ and CD1382
RPMI8226 cells grown in culture, before and after exposure to
TRAIL. (A) Relative total number (CD138++CD1382) of cells in culture at
the start of the experiment before the addition of TRAIL and after 48 h
of incubation with 25 ng/ml TRAIL. (B) Relative number of CD138+ and
CD1382 cells at the start before the addition of TRAIL and after 48 h of
incubation with TRAIL. (C) Susceptibility of purified CD138+ and CD1382
cells isolated from TRAIL-resistant and parental, TRAIL-sensitive
RPMI8226 culture. The susceptibility to TRAIL was determined using
MTS assay and expressed as a percentage of the untreated control
sample. Data represent the mean 61SD of the three independent
experiments. *** = p,0.001.
doi:10.1371/journal.pone.0035830.g007
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Figure 8. Expression of TRAIL receptors R1 and R2 on purified CD138+ and CD1382 RPMI8226, NCI H929 and OPM2 cells. Purified
CD138+ and CD1382 cells were incubated with mouse anti-human TRAIL receptor R1 and R2 PE-conjugated monoclonal antibodies and analysed by
flow cytometry to determine the percentage of labelled cells. The numbers indicate the percentage of receptor-positive cells. A, Representative
histograms showing expression of R1 (a and b, thick solid lines) and R2 (c and d, thick solid lines) in CD138+ (a and c) and CD1382 RPMI8226 cells (b
and d). The thin lines represent the appropriate isotype controls. B and C, Numerical representation of the percentage of CD138+ and CD1382 NCI
H929 and OPM2 cells expressing R1 and R2 receptors.
doi:10.1371/journal.pone.0035830.g008
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analysis revealed TRAIL R1 and R2 was expressed by CD138+
cells, although the level of expression varied between cell lines. A
small proportion of CD1382 RPMI8226 cells were shown to
express TRAIL R1 but not R2. CD1382 NCI H929 cells or
OPM2 cells did not express TRAIL R1 or R2 (Fig. 8).
Pre-incubation with DOX increases TRAIL sensitivity in
both CD138+ and CD1382 MM cells isolated from
patients with multiple myeloma
The potential of TRAIL to induce apoptotic cell death in
human CD138+ and CD1382 primary MM cells was investigated
in myeloma cells isolated from newly diagnosed, previously
untreated patients. Bone marrow samples from patients with
newly diagnosed MM were used for these experiments. CD138+
cells were isolated by immunomagnetic separation. The remaining
fraction was depleted of normal haemopoietic CD34+ cells to
generate a CD1382CD342 fraction. Both fractions were in-
cubated with DOX or TRAIL alone for 24 h, and TRAIL for
24 h after pre-incubation with DOX for 24 h. DOX alone and
TRAIL alone treated cells were also pre-incubated for 24 hours to
match the length of treatment of DOX pre-incubated TRAIL-
treated cells. Cytotoxicity was measured by MTS assay. The
sensitivity of both CD138+ and CD1382CD342 fractions was
variable amongst individual patients samples (Fig. 9). The highest
level of cytotoxicity was detected in cells treated with DOX and
TRAIL, and this was seen in all samples. In all patient samples the
cytotoxicity induced by the combination of DOX and TRAIL was
greater than the sum of individual agents alone. This applied to
both CD138+ as well as CD1382CD342 cells (p,0.05). In all
samples the CD1382CD342 cells were less sensitive to the actions
of DOX and TRAIL alone, or the combination DOX with
TRAIL, than CD138+ cells (Fig. 9).
Combined treatment with TRAIL and DOX results in
complete eradication of plasmacytomas derived from
CD1382 cells in NOD/SCID mice in vivo
To determine whether TRAIL (alone or in combination with
DOX) is also effective at inducing anti-myeloma activity in vivo we
used the NOD/SCID mouse xenograft model of subcutaneous
plasmacytoma growth initiated by implanting separated MM
CD1382 cells (Fig. 10). Mice were first irradiated and 24 hours
later CD1382 RPMI8226-GFP cells were injected subcutaneously
into the right flank. After three weeks mice developed palpable
tumours, were randomised into four groups and treated each day
for five consecutive days with subcutaneous injections of vehicle,
TRAIL and/or DOX. The first control group received PBS only,
the second received DOX and the third TRAIL. The fourth group
received DOX on the first and third day only and TRAIL on each
day (Fig. 10A). Treatment with TRAIL or DOX alone, for 5 days
resulted in a temporary inhibition of tumour growth (Fig. 10B),
however, long-term follow up demonstrated that tumour growth
continued once treatment had stopped. Thus using this regimen
treatment only delayed tumour growth (Fig. 10C). However, the
sequential treatment of DOX followed by TRAIL resulted in
complete eradication of tumours (Fig. 10C). Indeed, we could not
detect the presence of tumour even 90 days post treatment. Mice
were sacrificed at this time and individual organs examined for
evidence of tumour growth. No evidence of tumour growth was
detected. No observable toxicity or weight loss was observed in this
group.
Discussion
In this study we report that TRAIL can induce apoptosis of
different populations of myeloma cells. Importantly we show that
TRAIL treatment in combination with doxorubicin results in the
complete and sustained eradication of MM cells in vivo. Further-
more, we provide evidence that this treatment successfully
eliminates CD1382 cells, which have been implicated in initiating
myeloma growth [16].
In the present study we have shown that both CD138+ and
CD1382 cells, derived from either cell lines or from patient
samples, are susceptible to the actions of TRAIL, DOX and DEX.
Of note these cells were more susceptible to TRAIL than either
DOX or DEX. TRAIL when combined with DOX was shown to
have a more profound cytotoxic activity in both populations than
either agent alone. This is consistent with DOX upregulating/
reinstating TRAIL sensitivity in these cells [25,36]. We also
provide three lines of evidence suggesting that apoptosis is the
predominant mechanism of cell death induced by TRAIL.
Cytospin experiments demonstrated evidence of morphological
changes typical of apoptosis. Annexin V staining indicates changes
in cytoplasmic membrane typical of early apoptosis. Finally,
TRAIL was shown to induce caspase activity and induce apoptosis
via both extrinsic and intrinsic pathways. In contrast our data
suggests that DOX was unable to activate the extrinsic pathway,
and is only a weak inducer of the intrinsic pathway.
We also demonstrated that CD138+ cells were more susceptible
to TRAIL than CD1382 cells. This was seen in the human
myeloma cell lines RPMI8226, NCI H929 and OPM2 as well as in
cells isolated from patients with multiple myeloma. Although the
magnitude of response may differ this could reflect the relative
sensitivities of the different techniques used. The CD1382 cells
have been reported to have tumour-initiating properties and
support tumour growth in vivo [16]. Our studies also showed that
prolonged exposure of cells to TRAIL results in the appearance of
TRAIL resistant CD1382 cells. This increased drug resistance
Figure 9. In vitro sensitivity of CD138+ and CD1382 CD342 cells
isolated from MM patient bone marrow samples. Sensitivity of
CD138+ (+) and CD1382 CD342 (2) cells from individual MM patient
samples (P1–P5) to DOX (500 ng/ml, white bars), TRAIL (25 ng/ml,
hatched bars) after 24 h and TRAIL for 24 h after pre-incubation with
DOX for 24 h (black bars). Both arms of the study were time matched.
Cytotoxicity was measured by MTS assay and expressed as a percentage
of the untreated control sample. For more details about patient
samples processing and cell purification please see Materials and
Methods. Data represent the mean 61SD of the three independent
experiments. * = p,0.05, **p,0.01, ***p,0.001 and represent compar-
isons between CD1382 and CD138+ cells.
doi:10.1371/journal.pone.0035830.g009
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appears to be an important characteristic of cancer ‘‘stem’’ cells
[22,42]. This would argue that treatment in an in vivo or clinical
setting should be short-term in nature in order not to induce drug
resistance. Importantly, pre-treatment with doxorubicin and
subsequent exposure to TRAIL resulted in increased ability to
reduce viability of CD138+ and CD1382 cells in vitro. This was
seen in each of the cell lines examined. The source of the CD138+
cells in these cultures is unknown. Whether they are derived
directly from CD138+ cells or arise form the CD1382 population
is unclear.
In primary myeloma cells TRAIL was also able to induce
cytotoxicity. This was more pronounced in CD138+ when
compared to CD1382CD342 cells. Since this population may
contain the myeloma-initiating cells [16] our data suggest that the
clonogenic progenitor cells, whether they are in cell lines or
derived from patients, are less susceptible to the actions of TRAIL.
Figure 10. Complete eradication of established multiple myeloma plasmacytomas by combination therapy with TRAIL and
Doxorubicin. (A) Representative images of mice before the start of the therapy at day 24 (a, c, e, g) and three weeks after the end of treatment (b, d,
f, h). NOD/SCID mice were injected s.c. with CD1382 RPMI8226-GFP cells and tumours allowed to develop. Three weeks after inoculation, when the
tumours were palpable, mice were randomised into four groups and treated with PBS (a, b), DOX (c, d), TRAIL (e, f) or DOX+TRAIL (g, h) for five
consecutive days. DOX (1 mg/kg), TRAIL (10 mg/kg) and TRAIL+DOX (10 mg/kg daily+1 mg/kg on first and third day only) were administered s.c.
Tumour size was monitored every day during the treatment week and every second day for an additional three weeks using LIGHTools imaging. For
mice treated with PBS, DOX or TRAIL alone mice tumours continued to grow following cessation of treatment and reached a size requiring sacrifice.
For mice treated with DOX and TRAIL tumours never reappeared so were studied for at least 90 days before being sacrificed. (B) Graph representing
the mean tumour size for each group at a given day during the treatment period only. (C) Graph representing the mean tumour size for each group
at a given day during the entire experiment. Graphs were constructed by digital analyses of tumour pictures. Data represent the mean for individual
groups at each time point-SD data was omitted to improve the clarity of the final graph.
doi:10.1371/journal.pone.0035830.g010
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However, as with the cell lines combined treatment with TRAIL
and DOX significantly reduced the growth of CD1382CD342
cells. Unlike with CD1382 cells present in the RPMI8226, NCI
H929 and OPM2 cells combined treatment at the concentrations
used did not eradicate growth of primary myeloma cells in vitro.
The reason for the difference in sensitivity between primary cells
and the cell line cells is unclear, but may reflect differences in levels
of TRAIL receptors and/or downstream signalling components
between samples and cell lines. Certainly, our data demonstrated
differential expression of levels of TRAIL R1 and R2 amongst the
cells lines. To eradicate primary tumour cells completely, further
studies establishing optimum dosing regiments may be necessary.
Having demonstrated that treatment of TRAIL with DOX was
able to eradicate CD1382 cells in vitro we then investigated this in
vivo. Given that CD138+ and CD1382 were shown to be able to
develop resistance to the actions of TRAIL we chose to use short-
term treatment only. Once solitary plasmacytomas had been
established mice were treated for five days with TRAIL and/or
DOX and monitored for up to 90 days following treatment. Using
this treatment regime and a native TRAIL preparation rather
than forms of TRAIL used previously with FLAG, polyhistidine or
leucine zipper tags [35,40], we demonstrated that treatment with
TRAIL alone resulted in a rapid initial reduction in tumour size.
This reduction was only transient and further increase in tumour
size was apparent even during the treatment phase. The overall
result of this treatment was only to delay tumour growth. Similar
results were obtained with DOX only treatment. However, if
TRAIL was combined with DOX pre-treatment it was possible to
achieve total tumour eradication, using both fluorescence and
visual analysis, in all animals. This is consistent with reports that
DOX enhances sensitivity to TRAIL by multiple mechanisms.
Previous studies have shown that DOX potentiates the effect of
TRAIL by inducing expression of TRAIL death receptors DR4
and DR5 [36]. DOX may further enhance TRAIL mediated
apoptosis through induction and activation of pro-apoptotic
caspases and down-regulation of the inhibitors of the apoptosis
family of proteins (IAP) [43,44]. DOX also induces expression of
Smac/DIABLO, a suppressor of IAP, and ceramide production,
which enhances DR5 clustering in the cell membrane [45,46]. We
could not detect any tumour growth in animals treated with
a combination of DOX and TRAIL either in live mice or
following post-mortem analysis at 90 days, either following visual
analysis or fluorescence analysis. Although we cannot exclude the
possibility that tumours were present but too small to be detected
using these techniques it does support the suggestion that
combination therapy is able to cause a sustained eradication of
the tumour in vivo. We conclude, that as with combination
treatment in vitro, combination treatment in vivo is able to eradicate
both CD138+ and CD1382 cells. Importantly, the short-term
nature of the treatment and the combination with DOX prevents
the development of resistant cells. These findings may provide
a rational explanation for the failure of TRAIL alone to eradicate
tumours. This may have implications for treating cancer in
general. For example, it has been reported that mouse mammary
tumours, treated with chemotherapeutic agent cisplatin, become
more resistant to further treatment and contain proportionally
more cancer ‘‘stem’’ cells than responsive tumours [47]. High
frequencies of leukaemia stem cells have also been detected in
poor-outcome childhood precursor-B acute lymphoblastic leuke-
mias [48].
The anti-cancer potential of TRAIL (alone or in combination)
has been demonstrated in various in vivo models of tumour growth.
Colon, breast, prostate, glioma and MM tumours grown in mice
have all been shown to be susceptible to TRAIL [29,30,38,49,50],
however the reported efficacies of these treatments were variable.
This may reflect many factors including the design of the
experiment, the molecular form of the TRAIL protein used, the
appearance of resistant cells, the duration of treatment and the
length of tumour monitoring after cessation of treatment. For
example, the efficacy of treatment for prevention of tumour
establishment and growth was higher than for treatment of
established tumours [30,49]. Equally, the bigger the established
tumour prior to treatment, the less efficacious the treatment [30].
It has also been shown that preparations of TRAIL containing
non-native domains and/or requiring antibody for its polymeri-
sation are less efficient than the native form of TRAIL, at least in
in vitro experiments [51]. Extending the duration of treatment may
increase efficacy but also increases the probability of appearance of
resistant cells [50]. Data from clinical studies suggests that similar
processes might operate during treatment. Certainly treatment of
patients with myeloma usually involves administration of chemo-
therapeutic drugs over a period of weeks or months. The initial
treatment successfully reduces tumour burden, however, after
a period of time, patients relapse which often results in the
development of more resistant disease, which are increasingly
difficult to treat. However, our data would argue that for optimal
use of TRAIL it is important to consider using short-term
treatments and combining this with agents that may sensitise the
tumour cells to the action of TRAIL.
In summary, our data suggest that it is possible to eradicate
myeloma cell growth in vitro and in a model of solitary
plasmacytomas in vivo by targeting CD1382 myeloma cells with
TRAIL. Importantly, combining short-term TRAIL treatment
with DOX prevents the development of TRAIL resistant cells,
especially in clonogenic progenitor population, and the long-term
recovery of the tumour in vivo. We believe that the findings
presented here offer a promising new approach in the quest to
cure disseminated cancers such as MM.
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